Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: November 2024
Date Filed: November 12, 2024
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K serves as a notification to incorporate an exhibit by reference into existing registration statements rather than a financial report.
Material Changes
No material financial changes versus the prior comparable period are disclosed in this filing. The document focuses on the submission of an exhibit regarding clinical progress.
Guidance, Outlook, and Management Commentary
Exhibit Submission: The registrant submitted Exhibit 99.1, titled "ATH Presentation Tracking MSA Progression at Intl Symposium."
Registration Statements: This report is incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076).
Risks and Contingencies: No specific risks or contingencies are detailed in the text of this filing.
Investor Verification Checklist
- Review the content of Exhibit 99.1 ("ATH Presentation Tracking MSA Progression at Intl Symposium") for specific clinical trial updates.
- Verify the status of the referenced Form S-8 and Form F-3 registration statements for capital raising activities.
- Consult the company's most recent Form 20-F for detailed financial statements, as this Form 6-K contains no financial data.